LONDON, June 20, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today released the 2024 update to the Journal Citation Reports™ (JCR™). The reports provide an essential and comprehensive resource of high-quality journals, ranked by field to enable academic institutions, researchers and publishers to gauge the significance of journals in the global research landscape. Changes to journal rankings include the addition of the Emerging Sources Citation I ...

Core Insights - Major pharmaceutical companies are actively seeking partnerships or acquisitions with ADC developers to strengthen their oncology pipelines, as ADCs offer enhanced target specificity and a broader therapeutic index compared to traditional therapies [1][9]. Industry Overview - The ADC landscape is evolving, with over a dozen ADC therapies receiving global approval, and contract development manufacturing organizations (CDMOs) aiding in manufacturing challenges [5]. - The number of ADCs on the global market has increased into double digits over the past five years, indicating their growing significance in modern medicine [9]. Companies to Watch - The report highlights seven innovative companies that are making strides in drug discovery and development, particularly in advancing ADCs for targeted cancer treatments [13]. - Notable companies include: - **Adcendo ApS**: Focuses on ADCs targeting the uPARAP receptor in various cancers, aiming to replace conventional chemotherapy with targeted treatments [14]. - **Araris Biotech AG**: Utilizes proprietary technology for site-specific drug attachment to create more effective and less toxic ADCs [14]. - **GO Therapeutics**: Develops therapies against glycoprotein cancer targets using a platform-based approach [14]. - **Heidelberg Pharma AG**: Employs amanitin-based compounds as ADC payloads, targeting RNA polymerase II for improved treatment options [14]. - **Pheon Therapeutics**: Focuses on novel oncology targets and linker-payload technologies, with a lead program entering clinical stages in 2024 [14]. - **Tallac Therapeutics, Inc.**: Uses next-generation ADC technology with oligonucleotide payloads for targeted immune activation [14]. - **Tubulis**: Aims to deliver targeted anti-cancer agents with stable linkers to minimize offsite toxicities [14]. Methodology - The selection of companies in the report is based on various factors, including medical and business challenges, patient unmet needs, proof of concept, clinical trial positioning, financial health, and intellectual property status [3].

Core Insights - Clarivate Plc has launched Research Horizon Navigator™, an AI-native module within InCites Benchmarking & Analytics™, aimed at identifying emerging research topics for strategic investment and impact [1][3] - The tool utilizes data from the Web of Science Core Collection™ and a novel methodology from the Institute for Scientific Information (ISI)™ to highlight new research trends and interdisciplinary connections [2] Features of Research Horizon Navigator - The module labels each emerging topic with a research theme assigned by generative AI and provides interactive visualizations to show connections between papers, authors, and institutions [2] - It is designed to assist academics, funding agencies, and research organizations in identifying impactful areas for future investments and strategic planning [1][3] Applications and Benefits - Key applications include technology watch, collaboration discovery, funding program management, and research assessment, enabling institutions to monitor research landscapes and identify funding opportunities [5] - Feedback from the research community will guide further enhancements, ensuring the tool remains relevant and effective in identifying emerging research areas [4]

Strategic collaboration enhances insight into patient demographics and behaviors, enabling analytical precision in addressing population health outcomes LONDON, May 31, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced a strategic partnership with HealthWise Data, a leading healthcare data and analytics firm bridging the gap between clinical outcomes and Social Determinants of Health (SDoH) domains. The collaboration integrates SDoH att ...

Group 1 - Clarivate Plc announced the automatic and mandatory conversion of its 5.25% Series A Mandatory Convertible Preferred Shares into ordinary shares on June 3, 2024, with a conversion rate of 3.8462 ordinary shares per Preferred Share [1] - Holders of record as of May 15, 2024, will receive a final quarterly cash dividend of $1.3125 per Preferred Share on the conversion date [2] - Clarivate is recognized as a leading global provider of transformative intelligence, offering data, insights, analytics, and expert services across various sectors including Academia, Government, Intellectual Property, and Life Sciences [4]

Company Announcement - Clarivate Plc announced that its 5.25% Series A Mandatory Convertible Preferred Shares will automatically convert into ordinary shares on June 3, 2024, at a conversion rate of 3.8462 ordinary shares per Preferred Share [1] - Holders of record as of May 15, 2024, will receive a final quarterly cash dividend of $1.3125 per Preferred Share on the conversion date [2] Company Overview - Clarivate is a leading global provider of transformative intelligence, offering enriched data, insights, analytics, workflow solutions, and expert services across various sectors including Academia & Government, Intellectual Property, and Life Sciences & Healthcare [4]

Transforming the way libraries select, acquire and manage their collections of academic books SOURCE Clarivate Plc LONDON, May 30, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announces that 500 institutions around the world have selected the Rialto™ books marketplace solution with Florida Atlantic University as the 500th customer. This milestone, achieved in just a few years, underscores Rialto's rapid adoption and success in transforming t ...

LONDON, May 29, 2024 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) (the "Company" or "Clarivate"), a leading global provider of transformative intelligence, today announced that the Company will present at the following investor conferences in June 2024: Jonathan Gear, Chief Executive Officer, will present at the William Blair Growth Stock Conference on Tuesday, June 4, 2024, at 2:00 p.m. Central Time (3:00 p.m. Eastern Time). The live webcast can be accessed at https://wsw.com/webcast/blair97/clvt/1954890. Jo ...

Core Points - Clarivate Plc, a leading global provider of transformative intelligence, will present at two investor conferences in June 2024 [1] - Jonathan Gear, CEO, will present at the William Blair Growth Stock Conference on June 4, 2024, at 2:00 p.m. Central Time [1] - Jonathan Collins, CFO, will present at the Stifel Cross Sector Insight Conference on June 5, 2024, at 3:35 p.m. Eastern Time [1] - Live webcasts of the presentations will be available for investors [1] - A replay of each webcast will be accessible for 90 days on the company's investor relations website [2] Company Overview - Clarivate provides enriched data, insights, analytics, workflow solutions, and expert services in Academia & Government, Intellectual Property, and Life Sciences & Healthcare [3] - The company aims to deliver transformative intelligence to its clients [3]

New report highlights innovations poised to drive significant clinical and market impact LONDON, May 22, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the release of the Medical Technologies to Watch in 2024 report. This first installment of a two-part series offers a comprehensive predictive analysis of high-growth medical technology markets poised to generate over $1 billion in value or achieve double-digit growth within the next ...